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Abstract
The infectious agents, prions, are composed mainly of conformational 
isomers of the cellular prion protein (PrPc) in its abnormal accumulated scrapie 
forms (PrPSc). The distinct prion isolates or strains have been associated with 
different PrPSc prion protein conformations and patterns of glycosylation 
and are associated with disease progression and severity. In humans, sporadic 
Creutzfeldt-Jakob disease (sCJD) is the most common form and has been divided 
into six subtypes, based on PrPSc electrophoretic mobility and allelic varia-
tion at codon 129, among which sCJD MM1 and sCJD VV2 are the two most 
commonly occurring subtypes with known clinical manifestations. The strain-
specific response of PrPSc suggests both the molecular classification and the 
pathogenesis of prion diseases along with posttranslational modification of PrP 
in humans and animals.
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1. Introduction
For the last two decades, scientists have been working on the prion-related dis-
eases, though major features of this transmissible neurodegenerative disease are still 
not clear. Among some ambiguities, the prion strain phenomenon and the zoonotic 
potential are the most discussed and enigmatic questions.
Prion diseases are fatal neurodegenerative disorder linked with misfolding of 
the host-derived protein, named prion protein. The prevalence of the disease in 
human population is very low (i.e., ~1–2 cases per million) and affect typically 
aged people. Among this 15% showed genetic concomitant, i.e., point mutation in 
PRNP gene.
Prion diseases are also well-known risk factor for ruminants, including sheep 
and goats with scrapie, cattle with bovine spongiform encephalopathy, and 
recently cervids with chronic wasting diseases (CWD). The prion agent was not 
able to cross the species barriers between humans and ruminant to a high extent, 
until the new application livestock carcasses recycling into the ruminant alimen-
tary chain. This new implementation resulted in partial inactivation of the BSE 
prions and cemented the approach with zoonotic potential and spread in humans. 
This outbreak was famous as the mad cow disease in cattle and the variant CJD 
(vCJD) in humans. The prion strain diversity, potential to adapt from one host to 
another, is a mysterious character-impelled scientific community to uncover the 
concealed story behind.
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2. General background
2.1 The prion protein
Cellular form of prion protein PrPc (prion protein) also referred to as CD 230 
(cluster of differentiation 230) is coded from PRNP gene on the short arm of 
chromosome 20. The PRNP gene of mammals contains three exons. The open read-
ing frame (ORF) lies entirely within exon 3 which transcribes mRNA (2.1–2.5 kb 
length) with approximately 50 copies/cell in neurons [1, 2]. Physiological involve-
ment of prion protein is diverse, but the active contribution is reflected by the high 
level of PRNP sequence similarity and conservation across the species in mammals. 
The expression of PrPc is ubiquitous in mammals’ bodies, with the highest levels in 
immune regulatory cells and masses, suggesting a high degree of metabolic involve-
ment in both systems [3].
Cellular prion protein exists in multiple conformations in the cell. In humans, the 
newly synthesized and unprocessed PrPc is approximately 253 amino acids in length 
and has a molecular weight of 35–36 kDa. Mature PrPc, after posttranslational 
modifications, the physiological form of PrP constitutes 208 amino acid residues. 
PrPc is translocated to the ER lumen due to the presence of N-terminal signal 
peptide. Glycophosphotidyl (GPI) anchor is added after the removal of C-terminal 
signal peptide. After the addition of GPI anchor, PrPc is associated to the lipid rafts. 
Raft association of PrPc is necessary for the proper folding and glycosylation (at two 
asparagine residues, i.e., Asn 181 and Asn 197) taking place in ER [4] and formation 
of a disulfide linkage between the two cysteine residues, i.e., 179 and 214, in human 
PrP in the Golgi apparatus [5]. In addition, mature PrPc contains five octapeptide 
repeats with a sequence PHGGGWGQ near NH2-terminal that are encoded by 
codons 51–91 of the PRNP gene [6]. Physiological form of prion protein, PrPc, 
occurs predominantly along with the truncated, transmembrane COOH–terminal 
and transmembrane NH2-terminal forms, namely, PrP
Ctm and PrPNtm, respectively, 
due to transmembrane insertion of the hydrophobic pocket between aa 110 and 134 
[7, 8]. A GPI anchor is attached to PrPc during its life cycle in the cell [9].
In neurons, the cell surface retentivity is very short-lived, like other classical 
membrane receptors, i.e., a t1/2 of 3–5 min. The endocytosis is rather enigmatic. 
In different cells and different physiological conditions, internalization via both 
clathrin- and non-clathrin-coated vesicles is reported [10].
Structural studies of recombinant human PrPc reveal that the protein consists of 
three α-helices at aa residues 144–154, 175–193, and 200–219 and two small antipar-
allel β-sheets between aa residues 128–131 and 161–164 [11]. PrPc contains a flexible 
domain at N-terminal between amino acid positions 23–120, whereas a folded 
domain at C-terminal between amino acids 121–231.
The presence of the PrPc on cell surface suggests its role as a cell receptor. Many 
studies relate PrPc to diverse signaling pathways. The N-terminal domain contain-
ing the octapeptide repetitive motif is reported to exhibit a high affinity for copper 
ions (Cu2+), suggesting the involvement of PrPc in copper metabolism [12, 13]. PrP 
is also reported to regulate the influx of Zn2+ into the neuronal cells via α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors, by acting as a zinc 
sensor to the AMPA receptor acting as transporter for Zn2+. These results also sug-
gest that PrP-mediated zinc uptake may contribute to neurodegeneration in prion 
and other neurodegenerative diseases [14, 15]. PrPc also promotes cellular Ca2+ 
influx via VGCC [16, 17]. Likewise, the activation of Ras GTPases after interaction 
of PrPc leading to Erk activation is also reported [18]. Activation of protein kinase C 
and PI3 kinase/Akt signaling is also reported to be associated to PrP, but the mecha-
nism of activation is poorly understood [19, 20].
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Derivatives resulting from the various PrPc-proteolytic cleavages are associated 
to the alteration of PrPc physiology. An α-cleavage at aa residues 110/111 results 
in N1 and C1 fragments, whereas a β-cleavage event at aa residue 90 results in N2 
and C2 fragments. On the cell surface, some proportion of PrPc also undergoes an 
ADAM10-driven cleavage at GPI anchor called as shedding, resulting in the release 
of full-length PrPc molecule in extracellular milieu [21].
2.2 Prion diseases
Prion diseases, also known as transmissible spongiform encephalopathies 
(TSEs), are rare progressive, incurable fatal neurodegenerative diseases that have 
the property of transmissibility [2, 22, 23]. Prion diseases affect humans and ani-
mals. Human prion diseases include Creutzfeldt-Jakob disease (CJD), fatal familial 
insomnia (FFI), Gerstmann-Sträussler-Scheinker syndrome, variably protease-
sensitive prionopathy (VPSPr), vCJD, and Iatrogenic CJD (iCJD) [24]. Animal 
prion diseases include bovine spongiform encephalopathy (BSE) in cattle [25], 
chronic wasting disease (CWD) in deer and elk [26], and scrapie in sheep, goats and 
experimentally infected rodents [12].
Human prion diseases occur at a rate of one to two cases per million per year. 
Among human prion diseases, 80–95% are sporadic Creutzfeldt-Jakob disease 
(sCJD), 10–15% are genetic (often familial), and less than 1% are acquired. In 
sCJD, the conversion of PrPc to PrPSc is thought to occur spontaneously (or pos-
sibly through a somatic mutation of PRNP). In genetic prion diseases, it is thought 
that mutations in the prion protein gene, PRNP, make the PrPc more susceptible 
to changing conformation (misfolding) into PrPSc. In acquired forms, PrPSc is 
accidentally transmitted to a person, causing their endogenous PrPc to misfold [27].
Prion diseases belong to a growing family of protein misfolding diseases that are 
attributed to misfolding (conformational alterations) and aggregation of proteins 
in specific brain regions, including Alzheimer’s disease, Parkinson’s disease, and 
systemic amyloidosis [28, 29]. Some characteristic features of prion diseases are their 
wide phenotypic heterogeneity and their multiple modes of occurrence (sporadic, 
genetic, or acquired) [30, 31]. Central hypothesis in prion diseases is the conversion 
of an endogenous protease-sensitive cellular prion protein, PrPc, into a conforma-
tionally altered self-replicating protease-resistant pathological isoform, PrPSc [32], 
in the central and lymphoreticular systems. PrPSc binds to cellular PrPc and cata-
lyzes its conversion to an infectious form by nucleation and fragmentation cycle [33]. 
Prions are resistant to proteases, heat, and decontamination treatments, which is a 
major challenge for the prevention of prion diseases. Although protease-resistant pri-
ons correlate only slightly with infectivity, infectivity is linked to protease-sensitive 
oligomers [34]. PrPc-to-PrPSc conversion brings in neurotoxicity to the attributes of 
PrPSc [35]. Diseases arising due to prion misfolding are enlisted in Table 1.
Human prion diseases are characterized by a range of clinical symptoms and are 
classified by both clinico-pathological symptoms and etiology, with subclassifica-
tions according to the molecular features. Clinical manifestations include spongiform 
degeneration, motor and cognitive impairments, neuronal loss, gliosis, astrocytosis, 
and neuronal dysfunction [23]. Prion diseases have long incubation periods; once 
clinical symptoms appear, disease progresses very rapidly with lethality in all cases.
Sporadic Creutzfeldt-Jakob disease (sCJD) has average survival of about 
6 months, with 85–90% of patients dying within 1 year. The peak age of onset is 
55–75 years of age, with median age of onset of about 67 years and mean of 64 years 
[36]. Sporadic Creutzfeldt-Jakob disease has been classified based on combina-
tion of two features: a PRNP polymorphism at codon M129V [37] and the size of 
PK-digested PrPSc on Western blot giving two main types: type 1, with a more distal 
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cleavage site, are 21 kDa and type 2, with a more proximal cleavage site, are 19 kDa. 
These factors result in six possible combinations (MM1, MV1, VV1, MM2, MV2, 
and VV2) [36]. Codon 129 M/M homozygosity is reported to be associated with an 
early-onset and aggressive dementia in the CJD patients, whereas V/V homozygos-
ity correlates to a more prolonged pathology with ataxic onset [38]. Apart from 
codon 129, two other polymorphisms have been reported, i.e., N171S and E219K [39, 
40]. Disease-specific PrP mutations have been reviewed in detail by [41]. GSS asso-
ciated PRNP mutations include P102L, P105L, A117V, F198S, D202N, Q212P, and 
Q217R. PRNP mutations associated to fCJD include P102L, P105L, A117V, F198S, 
D202N, Q212P, and Q217R, whereas a single missense mutation (D178N) has been 
reported for FFI. This vast structural diversity and switching to disease causing 
PrPSc make prion protein and its derivatives interesting subject of study.
Although many laboratories are working on therapeutic strategies for prion 
disease, still they are incurable although some of the symptoms can be temporarily 
treated [27]. Three randomized double-blinded placebo-controlled trials have failed 
to alter disease outcome [27, 42].
3. Prion strains and impact on biological parameters
3.1 Prion strain diversity
Prion diseases affect a range of mammalian species and are caused by misfolding of 
normal cellular PrPc to self-propagating pathological isoform (PrPSc) [43]. Prions can 
form several distinct self-templating conformers, called prion strains (or variants), 
which confer dramatic variation in disease pathology and transmission [44]. Diverse 
strains of prions [45] exist and are operationally defined by differences in a heritable 
phenotype under controlled experimental transmission setups. Prion strains can differ 
in tissue tropism, incubation period, clinical signs of disease, and host range.
Phenotypes
Familial (inherited) Familial Creutzfeldt-Jakob-disease (fCJD)
Fatal familial insomnia (FFI)
Gerstmann-Sträussler-Scheinker disease (GSS)
Mixed or undefined forms
Sporadic CJD (sporadic)
Typical (MM1 and MV1)
Early onset (VV1)
Long duration (MM2)
Kuru plaques (MV2)
Ataxic (VV2)
Sporadic familial insomnia (sFI)
Acquired Kuru
Iatrogenic CJD (iCJD)
variant CJD (vCJD)
Modified [93].
Table 1. 
Classification of human prion disease.
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Prion disorders remain a challenge to modern science in the twenty-first century 
because of their strain diversity and interspecies transmission properties. Different 
clinicopathological properties of prion ailments are associated to biochemical 
heterogeneity in pathogenic protein. Unfortunately, little is known about the 
mechanisms that drive these differences in biochemical properties.
The mechanism by which a protein pathogen can encode strain diversity is 
only beginning to be understood. The identification of strain-specific cellular 
cofactors persuading the generation of new prion strains or the selection, from a 
conformationally heterogeneous population of PrPSc, of the most suitable prion 
conformation in a specific environment, denotes an important milestone toward 
the understanding of the mechanisms of prion strain diversity, which can have 
vital clinical and therapeutic implications. Adaptation to a new host is the basis of 
interspecies transmission of prion infections. In some cases, no abnormally folded 
PrP is found, reflecting a molecular species barrier to disease transmission [46, 47].
Although significant advancements have been made in comprehending the 
phenomenon of prion strains, many pieces of information are still missing, most 
important among them is the definitive evidence for the structural differences 
between prion strains and the relationship between the strain-specific properties of 
PrPSc and the resulting phenotype of disease [48, 49].
There are two main theories about possible interspecies transmission and adap-
tive properties of prion infections: the first one considers that strains are present as 
a single clone in inoculum, and if a new strain arises, it can be assumed that a stain 
shift has occurred. The second one considers that strains exist as a pool of different 
molecular species with a dominant type of PrPSc that is preferentially propagated 
in a given host, but in a different host, a minor PrPSc type can be favored, causing a 
shift in the strain. The second theory seems to better explain the high level of strain 
diversity that is reported from experimental data, although the likelihood that prion 
strains can infect the host as a single clone cannot be excluded. Plausible explanation 
for the second theory can be that from a pool of different conformations of PrPSc, 
only a specific fraction is able to replicate in a certain host species, in a manner that 
is dependent on the sequence and conformation of the PrPc, on the natural clear-
ance capacity of the infected cells [50–53] and on the presence of cofactors [54–56]. 
In such a model, a prion strain behaves as a quasi-species and represents a pool of 
molecules that are kept under control by the host [57]. Hence, in a given host, a 
strain will be constituted of a principal molecular component and a minor one.
Accordingly, interspecies transmission depends on compatibility between the 
conformation of pathological PrPSc and of the PrPc of the new host, on cell and 
tissue environment and cofactors [58, 59]. When a prion strain of one species 
infects an animal of a different species, there are two possible outcomes. The first is 
that the pathological PrPSc has no conformation compatibility with the host PrPc, 
resulting in non-conversion; in this case, the species barrier is defined as absolute. 
The second possibility is that the PrPSc conformation is compatible with the PrPc 
host conformation, allowing conversion and, ultimately, infection. In this case the 
proliferated strain can be identical to the infecting unit [60] or can change into a 
conformationally different strain due to cellular environment, polymorphisms, and 
cofactors [58, 59]. So, this type of transmission can facilitate the replication of the 
minor molecular component, if it is favored in the new host, or the generation of a 
new PrPSc different from the one of the inoculum [61, 62].
Many studies have been performed to reveal the nature of the cofactors that may 
be involved. It has been demonstrated that RNA molecules; protein chaperones, 
such as Hsp104 and GroEL; and others have been shown to change strain properties 
of prions highlighting the role of different cofactors in determining prion strain’ 
propagation properties.
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3.2 Transmissibility, heritable phenotype, and species barrier
In the early 1900s, the intraspecies transmission of the TSE agent was first docu-
mented with sheep scrapie [63]. The intraspecies transmission (i.e., sheep-sheep) 
showed marked attack rate as compared to the cross species transmission (i.e., 
sheep-mice) which showed incomplete attack rate and longer incubation periods. 
In cross species transmissions, the main hindrance was the adaptation of prion to its 
new host that leads to the vitiated prions after few subpassages, i.e., 2–3 passages. 
Previously, this phenomenon hindered the development of rodent models. Later, 
it has been reported that distinct prion strains, upon serial adaptation of sheep 
or goat scrapie isolates, could be raised and propagate in different lines of mice. 
The incubation time, disease severity, and vacuolation distribution in the brain 
of the mice-adapted strains showed marked signature of the specific disease [64]. 
However, the major goal at that time was to establish disease-specific end-stage 
response with clinical symptomatic phase leading to the anatomic distribution with 
significant lesion score profile. The first experiments reported inoculation of sheep 
scrapie to goats [65–67]. By that time, prion transmission from one species to the 
other, i.e., mink to small ruminants, was reported [68], and the bank vole showed 
maximum transmission capability and turned out as the universal prion strain 
acceptor [69–71]. In contrast, few studies also reported partial species barriers to 
pass prions from one species to another, i.e., scrapie isolates to cattle [72].
The emerging field of engineered transgenic mouse models, in combination 
with endogenous mouse PrP expression (presence or absence), significantly 
enhanced the possibilities for studying the zoonotic potential of prions [73–76]. In 
many cases, these experimental setups made emerged the idea that almost every 
prion could adapt to almost every PrP substrate, provided that some critical param-
eters have been set up in order to adapt the strain to its new host PrP [77–79]. The 
transmission efficacy of vCJD strain to wild-type mice also showed conserved and 
uniform characteristic BSE strain phenotype. The incubation period, glycoform 
analysis, and lesion profile did not show differential alterations in brain regions and 
in lymphoreticular tissue [80].
4. Prion strains and disease response
4.1 Phenotypic variants of PrP and human prion strains
The cellular prion protein is a product of PRNP gene-residing the chromosome 
20 in human. The conformational variations of PrPc in transmissible spongiform 
encephalopathies (TSEs) give rise to multiple phenotypic variants of PrP-scrapie 
form (PrPSc), referred to as prion strains. A pure strain refers to a molecular 
population of PrPSc with characteristic features such as incubation time, PrPSc 
distribution patterns, resultant spongiosis, and relative severity of the spongiform 
changes in the brain, when inoculated into distinct host species. In a given prion 
pathology, a strain species predominantly exists along with minimal concentrations 
of strains. Classically prion strains are classified based on abovementioned features. 
Characteristic pattern of prion strains on the western blotting has also been used 
for the strain classification. The differences of western blotting patterns occur due 
to the variability of proteinase k cleavage sites in prion protein and abundance of 
differential PrP glycoforms (i.e., di-glycosylated, mono-glycosylated, and un-
glycosylated isoforms). Rather recently, nontrivial approaches such as seeding 
potential of prion variants and differential strain-specific oligomeric populations 
have expanded the spectrum of strain classification [81].
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In human prion strains, variation is determined by proteinase K (PK) resistance. 
PK-resistant PrP occurs in two forms based on the migration on western blots, i.e., 
PrPSc type 1 migrates at 21 kDa, whereas type 2 PrPSc migrates at 19 kDa (resultant 
of two distinct PK digestion at amino acids 96 and 85, respectively) [82]. Atypical 
cases of variably protease-sensitive prionopathy (VPSPr) exhibit a different 
sensitivity profile to the Proteinase K. Some cases have been reported to exhibit 
no PK resistance (viz., protease-sensitive prionopathy, PSPr), whereas some other 
VPSPr cases present less PK resistance resulting in a ladder-like pattern on western 
blot ranging from 27 to 7 kDa. Details of human prion strains in combination with 
codon 129 M/V polymorphism are listed in Table 2 [83].
4.2 Templating activity
Prion templating activity coupled with the structure studies is also used as an 
index for strain classification. Baskakov and colleagues have been able to differenti-
ate the hamster recombinant PrP strains based on the structure profiles formed 
under different conditions, i.e., R and S fibrils, result of polymerization while 
rotating and shaking the monomers, respectively [84]. Structural validations of the 
prion protein polymers are challenging due to overly high hydrophobic nature of 
the polymers. For robust templating activity-based classification of prion strains, 
two methods have been established, namely, protein misfolding cyclic amplifica-
tion (PMCA) and real-time quacking-induced cyclic amplification (RT-QuIC), 
where prion strains are utilized as templates for the recombinant prion protein. 
Templating in PMCA is usually validated with downstream Western blotting, where 
RT-QuIC is a fluorometry-based method and provides the real-time information, 
utilizing thioflavin-T binding to polymers. Lag phase and final fluorescence signals 
could be used for discrimination between different prion strains [71]. RT-QuIC 
Strain type Histological characteristics Disease subtype, % 
age occurrence of all 
prion pathologies
MM/MV 1 Diffuse synaptic deposits sCJD, 40%
VV 2 Perineuronal and cerebellar plaque-like deposits sCJD, 15%
MV 2K Kuru plaques sCJD, 8%
MM 2C Cortical confluent vacuoles sCJD, 1%
MM 2T (sFI) Thalamo-olivary atrophy sCJD
VV 1 Corticostriatal synaptic deposits sCJD
MM 2V (vCJD) Florid plaques sCJD
MM/MV1+2C Mixed diffuse synaptic deposits and cortical confluent 
vacuoles
sCJD, 30%
MV 2K+C Mixed Kuru plaques and cortical confluent vacuoles sCJD
MM-VPSPr Large vacuoles, PrPSc microplaques in the molecular 
layer of the cerebellum, as well as target-like rounded 
formations of clusters of granules that increase in size 
toward the center
VPSPr
MV-VPSPr
VV-VPSPr
Modified from [83].
Abbreviations: BSE, bovine spongiform encephalopathy; sCJD, sporadic Creutzfeldt-Jakob disease; sFI, sporadic fatal 
insomnia; VPSPr, variably protease-sensitive prionopathy; gCJD, genetic CJD; GSS, Gerstmann-Sträussler-Scheinker 
disease; FFI, fatal familial insomnia; vCJD, variant CJD.
Table 2. 
Human prion strain histopathological profiles, influenced by codon 129 polymorphism determined in different 
backgrounds of human transmissible spongiform encephalopathies (TSEs).
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Figure 1. 
Prion strain emergence and interspecies transmission. The original prion strains were named as Kuru in 
human, BSE in cows, TSE in goat and sheep, and TME in minks. PMCA and RT-QuiC mobilized the prion 
strain characterization. The interspecies transmission of prions linked with host PrP oligomerization role, 
appearance of subassemblies named as quasispecies, tissue tropism, incubation period of prions, symptomatic 
stages of the diseases, and host range.
proves to be a highly specific and sensitive method and has been utilized to establish 
strain differences of typical and atypical prionopathies, e.g., the L-type BSE and 
classical BSEs [85].
A recent report showed oligo-/poly-thiophene derivate as a potent fluorescent 
approach to discriminate between prion strains [86]. The excitation/emission spec-
tra were obtained from the CWD and scrapie strains, and the interactive association 
between thiophene and different aggregates were used in combination with confor-
mational restriction to characterize different strains.
4.3 Distribution of density variants
Prion strain polymerization is a sequential process where single molecules are 
converted to polymers via a multitude of conformational variants. Different prion 
strains have been identified in animal and human cases based upon differential 
population densities of these quaternary structures [87]. Quaternary structure 
conformers of PrP have been isolated and studied using sucrose density gradient 
by many groups [88–91]. Differential prion strains have been also identified for the 
rapidly progressive forms of Alzheimer’s disease with distinct population of high-
density PrP oligomeric species [92].
5. Conclusions and future outlook
Prion strains and the interspecies barriers are still enigmatic phenomena. One 
of the surprising things about prion protein is that this single protein can fold up in 
9© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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so many different ways that are toxic and cause disease. Recent advances in PrPSc 
amplification methods, i.e., PMCA and RT-QuIC, might lead to clear improvements 
in the characterization of the prion strain.
From last many years, prion protein strain characterization and impact on dis-
ease are under debate. The use of prion transgenic models has been influential for 
studying and clarifying the molecular mechanisms in which the protein is involved. 
The ability to cross species barrier may be a result of either quasispecies theory 
or host PrP impact on progressive templating deformation upon oligomerization 
theory (Figure 1). These phenomena are mostly time dependent. By learning the 
structural variation and potential interspecies transmissions, we may progress 
toward the understanding of disease pathology and subsequently development of 
novel therapeutic approaches to such devastating disorders.
Acknowledgements
The study was performed within the recently established Clinical Dementia 
Center at the University Medical Hospital Goettingen and was partly supported by 
grants from the EU Joint Program Neurodegenerative Disease Research (JPND ± 
DEMTEST) (Biomarker-based diagnosis of rapid progressive dementias-optimi-
zation of diagnostic protocols, 01ED1201A). This work was supported by a grant 
from Helmholtz-Alberta Initiative-Infectious Diseases Research (HAI-IDR) and 
APRI-Human prions distinguishing sporadic from familial forms via structure and 
function as well as from the DZNE clinical project (Helmholtz).
Conflict of interest
We have no conflict of interest to declare.
Author details
Saima Zafar1,2*, Neelam Younas1,2, Mohsin Shafiq1,2 and Inga Zerr1,2*
1 Department of Neurology, Clinical Dementia Center, University Medical Center 
Goettingen (UMG), Georg-August University, Goettingen, Germany
2 German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
*Address all correspondence to: sz_awaan@yahoo.com  
and ingazerr@med.uni-goettingen.de
10
Prions - Some Physiological and Pathophysiological Aspects
References
[1] Liao YC, Lebo RV, Clawson GA, 
Smuckler EA. Human prion protein 
cDNA: Molecular cloning, chromosomal 
mapping, and biological implications. 
Science (80-). 1986;233:364-367
[2] Prusiner SB. Molecular biology 
of prion diseases. Science (80). 
1991;252:1515-1522. DOI: 10.1126/
science.1675487
[3] Linden R, Martins VR, Prado MAM, 
Cammarota M, Izquierdo I, Brentani 
RR. Physiology of the prion protein. 
Physiological Reviews. 2008;88:673-728. 
DOI: 10.1152/physrev.00007.2007
[4] Haraguchi T, Fisher S, Olofsson S, 
Endo T, Groth D, Tarentino A, et al. 
Asparagine-linked glycosylation 
of the scrapie and cellular prion 
proteins. Archives of Biochemistry 
and Biophysics. 1989;274:1-13. DOI: 
10.1016/0003-9861(89)90409-8
[5] Turk E, Teplow DB, Hood LE, 
Prusiner SB. Purification and 
properties of the cellular and scrapie 
hamster prion proteins. European 
Journal of Biochemistry. 1988;176: 
21-30. DOI: 10.1111/j.1432-1033.1988.
tb14246.x
[6] Owen F, Poulter M, Shah T, Collinge 
J, Lofthouse R, Baker H, et al. An 
in-frame insertion in the prion protein 
gene in familial Creutzfeldt-Jakob 
disease. Brain Research. Molecular Brain 
Research. 1990;7:273-276
[7] Hegde RS. A transmembrane form of 
the prion protein in neurodegenerative 
disease. Science (80-). 1998;279:827-834. 
DOI: 10.1126/science.279.5352.827
[8] Hegde RS, Voigt S, Lingappa VR.  
Regulation of protein topology by 
trans-acting factors at the endoplasmic 
reticulum. Molecular Cell. 1998;2:85-91. 
DOI: 10.1016/S1097-2765(00)80116-1
[9] Taylor DR, Hooper NM. The prion 
protein and lipid rafts. Molecular 
Membrane Biology. 2006;23:89-99. DOI: 
10.1080/09687860500449994
[10] Sunyach C. The mechanism 
of internalization of 
glycosylphosphatidylinositol-anchored 
prion protein. The EMBO Journal. 
2003;22:3591-3601. DOI: 10.1093/
emboj/cdg344
[11] Surewicz WK, Apostol MI. Prion 
protein and its conformational 
conversion: A structural 
perspective. Topics in Current 
Chemistry. 2011;305:135-168. DOI: 
10.1007/128_2011_165
[12] Stockel J, Safar J, Wallace AC, 
Cohen FE, Prusiner SB. Prion protein 
selectively binds copper (II) ions. 
Biochemistry. 1998;37:7185-7193. DOI: 
10.1021/bi972827k
[13] Dobson CM. Structural biology: 
Prying into prions. Nature. 2005;345: 
747-749. DOI: 10.1038/435747a
[14] He Q, Meiri KF. Isolation and 
characterization of detergent-resistant 
microdomains responsive to NCAM-
mediated signaling from growth cones. 
Molecular and Cellular Neurosciences. 
2002;19:18-31. DOI: 10.1006/
mcne.2001.1060
[15] Cooper DMF, Crossthwaite AJ.  
Higher-order organization and 
regulation of adenylyl cyclases. Trends in 
Pharmacological Sciences. 2006;27: 
426-431. DOI: 10.1016/j.tips.2006.06.002
[16] Herms JW, Korte S, 
Gall S, Schneider I, Dunker S, 
Kretzschmar HA. Altered intracellular 
calcium homeostasis in cerebellar 
granule cells of prion protein-deficient 
mice. Journal of Neurochemistry. 
2000;75:1487-1492. DOI: 
10.1046/j.1471-4159.2000.0751487
11
Prion Protein Strain Diversity and Disease Pathology
DOI: http://dx.doi.org/10.5772/intechopen.80702
[17] Fuhrmann M, Bittner T, Mitteregger 
G, Haider N, Moosmang S, Kretzschmar 
H, et al. Loss of the cellular prion 
protein affects the Ca2+ homeostasis in 
hippocampal CA1 neurons. Journal of 
Neurochemistry. 2006;98:1876-1885
[18] Stork PJS, Schmitt JM. Crosstalk 
between cAMP and MAP kinase 
signaling in the regulation of cell 
proliferation. Trends in Cell Biology. 
2002;12:258-266. DOI: 10.1016/
S0962-8924(02)02294-8
[19] Dekker LV, Palmer RH, Parker PJ.  
The protein kinase C and protein kinase 
C related gene families. Current Opinion 
in Structural Biology. 1995;5:396-402. 
Available from: http://www.ncbi.nlm.
nih.gov/pubmed/7583639
[20] Vassallo N, Herms J, Behrens C, 
Krebs B, Saeki K, Onodera T, et al. 
Activation of phosphatidylinositol 
3-kinase by cellular prion protein and 
its role in cell survival. Biochemical and 
Biophysical Research Communications. 
2005;332:75-82. DOI: 10.1016/j.
bbrc.2005.04.099
[21] Altmeppen HC, Puig B, Dohler F,  
Thurm DK, Falker C, Krasemann 
S. Proteolytic processing of the prion 
protein in health and disease. American 
Journal of Neurodegenerative Disease. 
2012;1:15-31
[22] Caughey B, Chesebro B.  
Transmissible spongiform 
encephalopathies and prion protein 
interconversions. Advances in Virus 
Research. 2001;56:277-311
[23] Collinge J. Prion diseases of humans 
and animals: Their causes and molecular 
basis. Annual Review of Neuroscience. 
2001;24:519-550
[24] Aguzzi A, Calella AM. Prions: 
Protein aggregation and infectious 
diseases. Physiological Reviews. 
2009;89:1105-1152. DOI: 10.1152/
physrev.00006.2009
[25] Hope J, Reekie LJ, Hunter N, 
Multhaup G, Beyreuther K, 
White H, et al. Fibrils from brains 
of cows with new cattle disease 
contain scrapie-associated protein. 
Nature. 1988;336:390-392. DOI: 
10.1038/336390a0
[26] Williams ES, Young S. Chronic 
wasting disease of captive mule deer: A 
spongiform encephalopathy. Journal of 
Wildlife Diseases. 1980;16:89-98
[27] Brown K, Mastrianni JA. The prion 
diseases. Journal of Geriatric Psychiatry 
and Neurology. 2010;23(4):277-298. 
DOI: 10.1177/0891988710383576
[28] Soto C. Unfolding the role of 
protein misfolding in neurodegenerative 
diseases. Nature Reviews. Neuroscience. 
2003;4:49-60. DOI: 10.1038/nrn1007
[29] Aguzzi A, Rajendran L. The 
transcellular spread of cytosolic 
amyloids, prions, and prionoids. 
Neuron. 2009;64:783-790. DOI: 
10.1016/j.neuron.2009.12.016
[30] McKintosh E, Tabrizi SJ, 
Collinge J. Prion diseases. Journal of 
Neurovirology. 2003;9:183-193
[31] Prusiner SB. Novel proteinaceous 
infectious particles cause scrapie. 
Science. 1982;216:136-144
[32] Caughey B. Prion protein 
conversions: Insight into mechanisms, 
TSE transmission barriers and 
strains. British Medical Bulletin. 
2003;66:109-120
[33] Knowles TPJ et al. An analytical 
solution to the kinetics of breakable 
filament assembly. Science. 
2009;326:1533-1537. DOI: 10.1126/
science.1178250
[34] Aguzzi A, Lakkaraju AKK. Cell 
biology of prions and prionoids: A 
status report. Trends in Cell Biology. 
2016;26:40-51. DOI: 10.1016/j.
tcb.2015.08.007
Prions - Some Physiological and Pathophysiological Aspects
12
[35] Norrby E. Prions and protein-
folding diseases. Journal of Internal 
Medicine. 2011;270:1-14. DOI: 
10.1111/j.1365-2796.2011.02387
[36] Puoti G, Bizzi A, Forloni G, 
et al. Sporadic human prion diseases: 
Molecular insights and diagnosis. Lancet 
Neurology. 2012;11(7):618-628. DOI: 
10.1016/S1474-4422(12)70063-7
[37] Lloyd SE, Mead S, Collinge 
J. Genetics of prion diseases. Current 
Opinion in Genetics and Development. 
2013;23:345-351. DOI: 10.1016/j.
gde.2013.02.012
[38] Palmer MS, Dryden AJ, Hughes 
JT, Collinge J. Homozygous prion 
protein genotype predisposes to 
sporadic Creutzfeldt-Jakob disease. 
Nature. 1991;352:340-342. DOI: 
10.1038/352340a0
[39] Kitamoto T, Tateishi J. Human prion 
diseases with variant prion protein. 
Philosophical Transactions of the 
Royal Society B: Biological Sciences. 
1994;343:391-398. DOI: 10.1098/
rstb.1994.003431
[40] Hizume M, Kobayashi A, Teruya 
K, Ohashi H, Ironside JW, Mohri S, 
et al. Human prion protein (PrP) 
219K is converted to PrPSc but shows 
heterozygous inhibition in variant 
Creutzfeldt-Jakob disease infection. 
The Journal of Biological Chemistry. 
2009;284:3603-3609. DOI: 10.1074/jbc.
M809254200
[41] Acevedo-Morantes CY, Wille H.  
The structure of human prions: 
From biology to structural models—
Considerations and pitfalls. Viruses. 
2014;6:3875-3892. DOI: 10.3390/
v6103875
[42] Kim MO, Geschwind MD. Clinical 
update of Jakob-Creutzfeldt disease. 
Current Opinion in Neurology. 
2015;28(3):302-310. DOI: 10.1097/
WCO.0000000000000197
[43] Colby DW, Prusiner SB. Prions. 
Cold Spring Harbor Perspectives in 
Biology. 2011;3(1):a006833. DOI: 
10.1101/cshperspect.a006833
[44] Stein KC, True HL. Extensive 
diversity of prion strains is defined by 
differential chaperone interactions and 
distinct amyloidogenic regions. PLoS 
Genetics. 2014;10(5):e1004337. DOI: 
10.1371/journal.pgen.1004337
[45] Safar JG. Molecular pathogenesis 
of sporadic prion diseases in man. 
Prion. 2012;6:108-115. DOI: 10.4161/
pri.18666
[46] Katorcha E, Gonzalez-
Montalban N, Makarava N, Kovacs 
GG, Baskakov IV. Prion replication 
environment defines the fate of prion 
strain adaptation. PLoS Pathogens. 
2018;14:e1007093. DOI: 10.1371/journal.
ppat.1007093
[47] Igel-Egalon A, Beringue V, Rezaei H, 
Sibille P. Prion strains and transmission 
barrier phenomena. Pathogens. 2018;7:5. 
DOI: 10.3390/pathogens7010005
[48] Crowell J, Hughson A, Caughey B, 
Bessen RA. Host determinants of prion 
strain diversity independent of prion 
protein genotype. Journal of Virology. 
2015;89:10427-10441. DOI: 10.1128/
JVI.01586-15
[49] Taguchi Y, Lu L, Marrero-
Winkens C, Otaki H, Nishida N, 
Schatzl HM. Disulfide-crosslink scanning 
reveals prion-induced conformational 
changes and prion strain-specific 
structures of the pathological prion 
protein PrP(Sc). Journal of Biological 
Chemistry. 2018;293:12730-12740. DOI: 
10.1074/jbc.RA117.001633
[50] Safar JG, DeArmond SJ, Kociuba K, 
Deering C, Didorenko S, Bouzamondo-
Bernstein E, et al. Prion clearance in 
bigenic mice. The Journal of General 
Virology. 2005;86:2913-2923. DOI: 
10.1099/vir.0.80947-0
13
Prion Protein Strain Diversity and Disease Pathology
DOI: http://dx.doi.org/10.5772/intechopen.80702
[51] Paar C, Wurm S, Pfarr W, 
Sonnleitner A, Wechselberger C.  
Prion protein resides in membrane 
microclusters of the immunological 
synapse during lymphocyte activation. 
European Journal of Cell Biology. 
2007;86:253-264. DOI:  10.1016/j.
ejcb.2007.03.001
[52] Wong E, Cuervo AM. Integration of 
clearance mechanisms: The proteasome 
and autophagy. Cold Spring Harbor 
Perspectives in Biology. 2010;2:a006734. 
DOI: 10.1101/cshperspect.a006734
[53] Mannini B, Cascella R, Zampagni M, 
van WaardeVerhagen M, Meehan 
S, Roodveldt C, et al. Molecular 
mechanisms used by chaperones to 
reduce the toxicity of aberrant protein 
oligomers. Proceedings of the National 
Academy of Sciences of the United States 
of America. 2012;109:12479-12484. 
DOI:  10.1073/pnas.1117799109
[54] Cohen FE, Pan KM, Huang Z, 
Baldwin M, Fletterick RJ, Prusiner 
SB. Structural clues to prion replication. 
Science. 1994;264:530-531. DOI: 
10.1126/science.7909169
[55] Deleault NR, Lucassen RW, 
Supattapone S. RNA molecules 
stimulate prion protein conversion. 
Nature. 2003;425:717-720. DOI: 
10.1038/nature01979
[56] Deleault NR, Walsh DJ, Piro JR,  
Wang F, Wang X, Ma J, et al. Cofactor 
molecules maintain infectious 
conformation and restrict strain 
properties in purified prions. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2012;109:E1938-E1946. 
DOI:  10.1073/ pnas.1206999109
[57] Weissmann C, Li J, Mahal SP, 
Browning S. Prions on the move. EMBO 
Reports. 2011;12:1109-1117. DOI: 
10.1038/embor.2011.192
[58] Hill AF, Collinge J. Prion strains 
and species barriers. Contributions 
to Microbiology. 2004;11:33-49. DOI: 
10.1159/000077061
[59] Hamir AN, Kehrli ME Jr, 
Kunkle RA, Greenlee JJ, Nicholson EM, 
Richt JA, et al. Experimental 
interspecies transmission studies 
of the transmissible spongiform 
encephalopathies to cattle: Comparison 
to bovine spongiform encephalopathy in 
cattle. Journal of Veterinary Diagnostic 
Investigation. 2011;23:407-420. DOI: 
10.1177/1040638711403404
[60] Collinge J, Clarke AR. A general 
model of prion strains and their 
pathogenicity. Science. 2007;318:930-936. 
DOI: 10.1126/science.1138718
[61] Bessen RA, Marsh RF. Identification 
of two biologically distinct strains of 
transmissible mink encephalopathy 
in hamsters. The Journal of General 
Virology. 1992;73:329-334. DOI: 
10.1099/0022-1317-73-2-329
[62] Bartz JC, Bessen RA, McKenzie D, 
Marsh RF, Aiken JM. Adaptation 
and selection of prion protein strain 
conformations following interspecies 
transmission of transmissible mink 
encephalopathy. Journal of Virology. 
2000;74:5542-5547. DOI: 10.1128/
JVI.74.12.5542-5547.2000
[63] Cuillé J, Chelle PL. La tremblante 
dumouton est bien inoculable. Comptes 
Rendus de l'Académie des Sciences. 
1938;206:78-79
[64] Houston F, Andreoletti O. The 
zoonotic potential of animal prion 
diseases. Handbook of Clinical 
Neurology. 2018;153:447-462. DOI: 
10.1016/B978-0-444-63945-5.00025-8
[65] Plummer PJ. Scrapie—A disease 
of sheep: A review of the literature. 
Canadian Journal of Comparative 
Medicine and Veterinary Science. 
1946;10:49-54
[66] Pattison IH, Gordon WS, Millson 
GC. Experimental production of 
Prions - Some Physiological and Pathophysiological Aspects
14
scrapie in goats. Journal of Comparative 
Pathology and Therapeutics. 
1959;69:300IN19-312IN20
[67] Pattison IH, Millson GC. Scrapie 
produced experimentally in goats 
with special reference to the clinical 
syndrome. Journal of Comparative 
Pathology. 1961;71:101-109
[68] Hadlow WJ, Race RE, Kennedy RC.  
Experimental infection of sheep 
and goats with transmissible mink 
encephalopathy virus. Canadian Journal 
of Veterinary Research. 1987;51:135-144
[69] Nonno R, Bari MAD, Cardone F,  
Vaccari G, Fazzi P, Dell’Omo G, 
et al. Efficient transmission and 
characterization of Creutzfeldt-Jakob 
disease strains in Bank voles. PLoS 
Pathogens. 2006;2:e12. DOI: 10.1371/
journal.ppat.0020012
[70] Watts JC, Giles K, Patel S, Oehler A,  
DeArmond SJ, Prusiner SB. Evidence that 
bank vole PrP is a universal acceptor for 
prions. PLoS Pathogens. 2014;10:e1003990
[71] Orrú CD, Groveman BR, 
Raymond LD, Hughson AG, Nonno R, 
Zou W, et al. Bank vole prion protein 
as an apparently universal substrate 
for RT-QuIC-based detection and 
discrimination of prion strains. PLOS 
Pathogens. 2015;11:e1004983. DOI: 
10.1371/journal.ppat.1004983
[72] Robinson MM, Hadlow WJ, 
Knowles DP, Huff TP, Lacy PA, 
Marsh RF, et al. Experimental infection 
of cattle with the agents of transmissible 
mink encephalopathy and scrapie. 
Journal of Comparative Pathology. 
1995;113:241-251
[73] Collinge J, Palmer MS, Sidle KC, Hill 
AF, Gowland I, Meads J, et al. Unaltered 
susceptibility to BSE in transgenic 
mice expressing human prion protein. 
Nature. 1995;378:779-783
[74] Büeler H, Aguzzi A, Sailer A, 
Greiner R-A, Autenried P, Aguet M, 
et al. Mice devoid of PrP are resistant to 
scrapie. Cell. 1993;73:1339-1347
[75] Telling GC, Scott M, Hsiao KK, 
Foster D, Yang SL, Torchia M, et al. 
Transmission of Creutzfeldt-Jakob 
disease from humans to transgenic 
mice expressing chimeric human-
mouse prion protein. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
1994;91:9936-9940
[76] Brandner S, Isenmann S, Raeber A, 
Fischer M, Sailer A, Kobayashi Y, et al. 
Normal host prion protein necessary for 
scrapie-induced neurotoxicity. Nature. 
1996;379:339-343
[77] Ghaemmaghami S, Watts JC, 
Nguyen HO, Hayashi S, DeArmond SJ,  
Prusiner SB. Conformational 
transformation and selection of 
synthetic prion strains. Journal of 
Molecular Biology. 2011;413:527-542. 
DOI: 10.1016/j.jmb.2011.07.021
[78] Baskakov IV. The many shades 
of prion strain adaptation. Prion. 
2011;8:27836
[79] Bian J, Khaychuk V, Angers RC, 
Fernandez-Borges N, Vidal E, Meyerett-
Reid C, et al. Prion replication without 
host adaptation during interspecies 
transmissions. Proceedings of the 
National Academy of Sciences 
of the United States of America. 
2017;114:1141-1146. DOI: 10.1073/
pnas.1611891114.
[80] Ritchie DL, Boyle A, McConnell I,  
Head MW, Ironside JW, Bruce 
ME. Transmissions of variant 
Creutzfeldt-Jakob disease from brain and 
lymphoreticular tissue show uniform 
and conserved bovine spongiform 
encephalopathy-related phenotypic 
properties on primary and secondary 
passage in wild-type mice. Journal of 
15
Prion Protein Strain Diversity and Disease Pathology
DOI: http://dx.doi.org/10.5772/intechopen.80702
General Virology. 2009;90:3075-3082. 
DOI: 10.1099/vir.0.013227-0
[81] Aguzzi A, Heikenwalder M, 
Polymenidou M. Insights into prion 
strains and neurotoxicity. Nature 
Reviews. Molecular Cell Biology. 
2007;8:552-561. DOI: 10.1038/nrm2204
[82] Disease SC, Parchi P, Castellani R,  
Capellari S, Ghetti B, Young K, 
et al. Molecular basis of phenotypic 
variability in sporadic Creutzfeldt-Jakob 
disease. Annals of Neurology. 1996;39: 
767-778.
[83] Kretzschmar H, Tatzelt J. Prion disease: 
A tale of folds and strains. Brain Pathology 
(Zurich, Switzerland).2013;23:321-332. 
DOI: 10.1111/bpa.12045
[84] Makarava N, Ostapchenko VG,  
Savtchenko R, Baskakov IV.  
Conformational switching within 
individual amyloid fibrils. The 
Journal of Biological Chemistry. 
2009;284:14386-14395. DOI: 10.1074/
jbc.M900533200
[85] Candelise N, Schmitz M, Da Silva 
Correia SM, Arora AS, Villar-Piqué A,  
Zafar S, et al. Applications of 
the real-time quaking-induced 
conversion assay in diagnosis, prion 
strain-typing, drug pre-screening 
and other amyloidopathies. 
Expert Review of Molecular 
Diagnostics. 2017;17:897-904. DOI: 
10.1080/14737159.2017.1368389
[86] Magnusson K, Simon R, 
Sjölander D, Sigurdson CJ, 
Hammarström P, Nilsson 
KPR. Multimodal fluorescence 
microscopy of prion strain specific PrP 
deposits stained by thiophene-based 
amyloid ligands. Prion. 2014;8:319-329
[87] Strains P, Phenomena TB. Prion 
strains and transmission barrier 
phenomena. Pathogens. 2018;7:5. DOI: 
10.3390/pathogens7010005
[88] Kim C, Haldiman T, Surewicz K, 
Cohen Y, Chen W, Blevins J, et al. 
Small protease sensitive oligomers 
of PrPSc in distinct human prions 
determine conversion rate of PrPC. 
PLoS pathogens. 2012;8:e1002835. DOI: 
10.1371/journal.ppat.1002835
[89] Peden AH, Sarode DP, 
Mulholland CR, Barria MA, Ritchie DL, 
Ironside JW, et al. The prion protein 
protease sensitivity, stability and 
seeding activity in variably protease 
sensitive prionopathy brain tissue 
suggests molecular overlaps with 
sporadic Creutzfeldt-Jakob disease. Acta 
Neuropathologica Communications. 
2014;2:1-17. DOI: 10.1186/
s40478-014-0152-4
[90] Cohen ML, Kim C, Haldiman T,  
Elhag M, Mehndiratta P, Pichet T, 
et al. Rapidly progressive Alzheimer ’ 
s disease features distinct structures of 
amyloid-b. Brain. 2015;138:1009-1022. 
DOI: 10.1093/brain/awv006
[91] Hartmann A, Muth C, Dabrowski O, 
Krasemann S, Glatzel M. Exosomes and 
the prion protein: More than one truth. 
Frontiers in Neuroscience. 2017;11:1-7. 
DOI: 10.3389/fnins.2017.00194
[92] Zafar S, Shafiq M, Younas N, 
Schmitz M, Ferrer I, Zerr I. Prion 
protein interactome: Identifying novel 
targets in slowly and rapidly progressive 
forms of Alzheimer’s disease. Journal of 
Alzheimer's Disease. 2017;59:265-275. 
DOI: 10.3233/JAD-170237
[93] Gambetti P, Kong Q, Zou W, Parchi P, 
Chen SG. Sporadic and familial CJD: 
Classification and characterisation. 
British Medical Bulletin. 2003;66:213-239. 
DOI: 10.1093/bmb/dg66.213
